)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
BioArctic (BIOA) investor relations material
BioArctic Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary28 Aug, 2025
Executive summary
Achieved record royalties and milestone payments in Q2 2025, driven by strong Leqembi sales growth and a major Novartis partnership, with approvals in nearly 50 countries and launches in Austria and Germany.
Advanced pipeline with exidavnamab progressing in Phase 2a for Parkinson’s and MSA, with orphan designation in US/EU and patent protection extended to 2041.
Launched 2030 ambitions focused on pipeline expansion, global partnerships, and sustainable profitability.
Strengthened position as a platform company with proprietary brain transporter technology and multiple partnerships, including a $30M upfront and up to $802M in milestones from Novartis.
European Commission granted Marketing Authorisation for Leqembi, triggering a EUR 20M milestone payment.
Financial highlights
Q2 2025 net revenues reached SEK 392 million, up from SEK 50 million year-over-year, with royalty revenue of SEK 162.5 million and a one-time stocking effect in China.
Operating profit for Q2 was SEK 179 million; net profit was SEK 97 million, compared to a loss in Q2 2024, impacted by currency effects and tax.
Cash and short-term investments at quarter-end totaled SEK 1.9 billion, bolstered by milestone and upfront payments.
Operating cash flow exceeded SEK 1.1 billion in Q2, driven by milestone and upfront payments.
Leqembi royalties increased 280% year-over-year and 60% sequentially from Q1 2025.
Outlook and guidance
Leqembi is on track to meet or exceed Eisai’s FY2025 sales forecast of JPY 76.5 billion, with strong momentum in all major markets.
Recurring revenue expected to increase in 2025, with further launches and regulatory milestones anticipated, and profitability expected from 2026 onwards.
Subcutaneous auto-injector for Leqembi anticipated to drive further growth upon approval, with US FDA decision expected soon.
European launches to roll out gradually through 2026, with early access in France and Spain and Nordic launches expected next year.
Operating expenses projected to rise due to commercial build-up and expanded R&D.
Leqembi EU launch: expected royalty ramp-up?
Novartis deal: BrainTransporter platform strategy?
Exidavnemab MSA: next clinical milestones?
Leqembi EU launch challenges and mitigation?
BrainTransporter tech: unique safety profile?
Exidavnemab next development phase strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioArctic earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
BioArctic AB is a research intensive biopharmaceutical company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 1993 based on scientific research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer and Parkinson projects.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage